TY - JOUR
T1 - Histopathologic differences account for racial disparity in uterine cancer survival
AU - Smotkin, David
AU - Nevadunsky, Nicole S.
AU - Harris, Kimala
AU - Einstein, Mark H.
AU - Yu, Yiting
AU - Goldberg, Gary L.
PY - 2012/12
Y1 - 2012/12
N2 - Objective: The incidence for uterine cancers has been reported to be higher among white women, whereas mortality is higher among black women. Reasons for the higher mortality among black women are not completely understood. The aim of our study is to examine the relationship between race/ethnicity, histopathologic subtype, and survival in uterine cancer. Methods: We abstracted socio-demographic, treatment, and survival data for all women who were diagnosed with uterine cancer at Montefiore Medical Center from January 1999 through December 2009. Pathology records were reviewed. Results: 984 patients were identified. Racial/ethnic distribution was 382 (39%) white, 308 (31%) black, 232 (24%) Hispanic, and 62 (6.3%) other races, mixed, or unknown. 592 (60%) patients had endometrioid histology. Blacks were much more likely than whites to have non-endometrioid histologies (p < 0.001), including papillary serous, carcinosarcoma, and leiomyosarcoma. Blacks and Hispanics were at least as likely as whites to receive either chemotherapy or radiation therapy. The hazard ratio for death for black versus white patients was 1.94 (p < 0.001) when all histological subtypes were included. The hazard ratio for Hispanics for death was 1.2 (p = 0.32) compared to whites. However, when patients were divided into endometrioid and non-endometrioid histological subtypes, there was no significant difference in survival by race/ethnicity. Conclusion: Black patients with uterine cancer are much more likely to die and are much more likely to have non-endometrioid histologies than white patients. There are no differences in survival among white, black, or Hispanic women with uterine cancer, after control for histological subtype.
AB - Objective: The incidence for uterine cancers has been reported to be higher among white women, whereas mortality is higher among black women. Reasons for the higher mortality among black women are not completely understood. The aim of our study is to examine the relationship between race/ethnicity, histopathologic subtype, and survival in uterine cancer. Methods: We abstracted socio-demographic, treatment, and survival data for all women who were diagnosed with uterine cancer at Montefiore Medical Center from January 1999 through December 2009. Pathology records were reviewed. Results: 984 patients were identified. Racial/ethnic distribution was 382 (39%) white, 308 (31%) black, 232 (24%) Hispanic, and 62 (6.3%) other races, mixed, or unknown. 592 (60%) patients had endometrioid histology. Blacks were much more likely than whites to have non-endometrioid histologies (p < 0.001), including papillary serous, carcinosarcoma, and leiomyosarcoma. Blacks and Hispanics were at least as likely as whites to receive either chemotherapy or radiation therapy. The hazard ratio for death for black versus white patients was 1.94 (p < 0.001) when all histological subtypes were included. The hazard ratio for Hispanics for death was 1.2 (p = 0.32) compared to whites. However, when patients were divided into endometrioid and non-endometrioid histological subtypes, there was no significant difference in survival by race/ethnicity. Conclusion: Black patients with uterine cancer are much more likely to die and are much more likely to have non-endometrioid histologies than white patients. There are no differences in survival among white, black, or Hispanic women with uterine cancer, after control for histological subtype.
KW - Disparity
KW - Histology
KW - Racial
KW - Survival
KW - Uterine cancer
UR - http://www.scopus.com/inward/record.url?scp=84868600198&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84868600198&partnerID=8YFLogxK
U2 - 10.1016/j.ygyno.2012.08.025
DO - 10.1016/j.ygyno.2012.08.025
M3 - Article
C2 - 22940487
AN - SCOPUS:84868600198
SN - 0090-8258
VL - 127
SP - 616
EP - 619
JO - Gynecologic Oncology
JF - Gynecologic Oncology
IS - 3
ER -